| Filed On | Filing |
|---|---|
| 17 May 2021 |
8-K/A: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Initiated Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma (NHL), interim clinical data expected in late 2021 |
| 01 Oct 2020 |
8-K/A: Changes in Registrant's Certifying Accountant
We have read the statements made by Adicet Bio, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Adicet Bio, Inc. dated September 25, 2020. We agree... |
Loading...
